BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.

Biotechnology

BioInvent International

Martin Welschof

Ingunn Munch Lindvig

Maria Stenbäck

Ingrid Teige

Emma Meurling

Björn Frendéus

Sylvie Ryckebusch

Marie Moores

Andres Mcallister

Stefan Ericsson

Research and Development

Quality Assurance and Control

Leadership Team

Project Management Team

Teams at BioInvent International

Research and Development

Quality Assurance and Control

Leadership Team

Project Management Team